EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine

Jale Boral iD, Nora Toft, Alp Eren Baybes, Chaitanya Tellapragada iD, Oleksandr Nazarchuk, Celine Fernandez, Christian Giske, Kristian Riesbeck iD

JAC-Antimicrobial Resistance · 07.01.2026 · 8 (1)

DOI: 10.1093/jacamr/dlaf256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 21.01.2026. Verfasst von Jale Boral und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anna and Edwin Berger Foundation, Swedish Heart-Lung Foundation, Forssman’s Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Escalating resistance among Gram-negative pathogens limits β-lactam options. Cefepime/enmetazobactam combines a fourth-generation cephalosporin with a class A β-lactamase inhibitor. We evaluated its activity against multidrug, extensive and pandrug-resistant war-wound isolates from Ukraine. Materials and methods We tested 215 clinical samples (2022–2023) isolated from wounded patients in Ukraine by broth microdilution. Paired comparisons of cefepime monotherapy versus cefepime/enmetazobactam was done to evaluate enmetazobactam. Whole-genome sequencing (n = 83) identified β-lactamases, sequence types and outer-membrane protein alterations.

Results

Across Enterobacterales, resistance decreased from 60.5% (26/43) with cefepime to 27.9% (12/43) with the cefepime/enmetazobactam combination. In K. pneumoniae, resistance declined from 92.6% (75/81) to 74% (60/81) and in P. mirabilis, from 88.9% (8/9) to 11.1% (1/9), respectively. P. aeruginosa showed a modest change [77.8% (23/36) to 58.3% (32/36)], while A. baumannii remained non-susceptible to both cefepime and cefepime/enmetazobactam with the rates of 91.3% (42/46) to 82.6% (36/46), respectively. Genotype–phenotype correlation revealed that in K. pneumoniae, reduced activity was associated with OmpK36 loop-3 insertions, OmpK35 loss and metallo-β-lactamases, whereas selected sequence types lacking these changes were more susceptible. In A. baumannii, OXA-type carbapenemases and blaADC beta-lactamases predominated; isolates lacking type VI secretion, omp33-36 and adhesin genes (ata/bap) demonstrated relatively higher susceptibility to cefepime/enmetazobactam.

Conclusions

Cefepime/enmetazobactam improved susceptibility relative to cefepime, most notably in Enterobacterales, but activity was constrained by permeability defects and non-target β-lactamases. Combination therapy with agents that does not get hydrolysed by MBLs and integrated β-lactamase detection with practical permeability indicators may optimize the clinical use of this combination in high-resistance settings.

Autor:innen und Institutionen

  • Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden.
  • School of Medicine, Koç University, Istanbul, Türkiye.
  • Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Center for Thermal Injury and Plastic Surgery, Vinnytsya Regional Clinical Hospital Named After Pirogov, Vinnytsya, Ukraine.
  • Department of Microbiology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine.
  • Medical Department, ADVANZ Pharma, Helsingborg, Sweden.

ORCID-Profile: Jale Boral, Chaitanya Tellapragada, Kristian Riesbeck

Förderung

  • Anna and Edwin Berger Foundation
  • Swedish Heart-Lung Foundation
  • Forssman’s Foundation
  • Royal Physiographic Society of Lund
  • Skåne County Council’s Research and Development Foundation
  • Swedish Research Council

Zitieren

APA

Boral, J., Toft, N., Baybes, A. E., Tellapragada, C., Nazarchuk, O., Fernandez, C., Giske, C., & Riesbeck, K. (2026). Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine. JAC-Antimicrobial Resistance, 8(1). https://doi.org/10.1093/jacamr/dlaf256

Vancouver

Boral J, Toft N, Baybes AE, Tellapragada C, Nazarchuk O, Fernandez C, et al. Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine. JAC-Antimicrobial Resistance. 2026;8(1). doi:10.1093/jacamr/dlaf256

BibTeX
@article{Boral2026,
  author = {Boral, Jale and Toft, Nora and Baybes, Alp Eren and Tellapragada, Chaitanya and Nazarchuk, Oleksandr and Fernandez, Celine and Giske, Christian and Riesbeck, Kristian},
  title = {Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/jacamr/dlaf256}
}
Kostenlos starten →